Beam Therapeutics' BEAM-301 Eliminates Starch Supplementation in Two Patients in Early Trial
Bitget2026/10/27 11:09- Beam Therapeutics reported initial Phase 1/2 results for BEAM-301 in six patients with glycogen storage disease type Ia on Oct. 27, 2026.
- Two of three patients receiving 40 mg achieved 15 hours of controlled fasting, eliminating daily starch supplementation at their latest assessments.
- Median fasting tolerance at Day 36 rose from 2.5 to 15 hours with 40 mg, versus 2.9 to 4.3 hours with 20 mg.
- Four of six patients experienced serious treatment-related adverse events; no dose-limiting toxicities occurred.
- Enrollment in the 60 mg cohort is underway; the company plans FDA discussions on a potential approval pathway.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Terranor Group schedules Q3 results presentation
WTI crude oil futures prices fall by more than 1%
Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment
According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.
GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions
Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.
Crypto prices
More
